Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by IrishCanuckon Aug 10, 2021 1:19pm
155 Views
Post# 33678815

RE:From May/6/2020

RE:From May/6/2020

Those three paragraphs have no coherent connection

Duster340 wrote:

“The world is in desperate need of safer therapies for pain and inflammation,” Dr Stauffer said. “Antibe represents one of the few truly novel platforms in the field, and I look forward to playing a role in navigating its drug pipeline through the later stages of clinical development, and ultimately providing patients with a safer treatment paradigm for pain management.”

In connection with Dr Stauffer’s appointment, the company has granted him a total of 500,000 restricted share units (RSUs). All RSUs are subject to time-based vesting; one-third of the RSUs granted will vest on each of the first, second and third anniversaries of today’s date.)
Duster340 writes: lets say the stock price was @ $4.00 on may/6th/2021 stauffer got 1/3 of 500k which is 166.66k x 4 = 666.64 thousand not bad. even at $1.50 per share he would have made a cool 250 thousand all these guys are getting paid huge money regardless of how the stock performs. how did you guys make out.  it,s a scam they have a drug that is not what they pump it up to be, all they have to do is drag it out as many years as possible and they get rich off of the rsu's. they are not alone how many other companies do you know of that where hyped, and then crashed and burned, the old pump and dump, totaly legal though, the rich get richer while share holders pay the price. i feel sorry for you guys. i hope this is not the case here but will only be known in time.
glta  



<< Previous
Bullboard Posts
Next >>